{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:48:44Z","timestamp":1792054124663,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.psychres.2026.117346","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:40:37Z","timestamp":1785307237000},"page":"117346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evolving patterns of antipsychotic use and polypharmacy for schizophrenia in Hong Kong: a 21-year longitudinal study"],"prefix":"10.1016","volume":"364","author":[{"given":"Eunice Kehui","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent KC","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3102-9992","authenticated-orcid":false,"given":"Shek-Ming","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caige","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chui Kwan","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Tsz Tsun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-0014","authenticated-orcid":false,"given":"Ian CK","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Yu Hai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9470","authenticated-orcid":false,"given":"Esther W","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2026.117346_bib0001","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.euroneuro.2024.04.012","article-title":"Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: a narrative review and recommendation for clinical practice","volume":"84","author":"Agid","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2026.117346_bib0002","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40801-025-00511-z","article-title":"Real-world prescribing patterns of long-acting injectable antipsychotics in australian psychiatric inpatients: trends, clinical outcomes, and substance use prevalence: Tumilara akindele, Kanchana de Alwis","volume":"12","author":"Akindele","year":"2025","journal-title":"Drugs-Real World Outcomes"},{"key":"10.1016\/j.psychres.2026.117346_bib0003","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. The American psychiatric association practice guideline for the treatment of patients with schizophrenia: American Psychiatric Association Publishing; 2020.","DOI":"10.1176\/appi.books.9780890424841"},{"issue":"5","key":"10.1016\/j.psychres.2026.117346_bib0004","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","article-title":"Antipsychotic polypharmacy in schizophrenia: benefits and risks","volume":"25","author":"Barnes","year":"2011","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.psychres.2026.117346_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","article-title":"Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia"},{"key":"10.1016\/j.psychres.2026.117346_bib0006","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jpsychires.2022.08.013","article-title":"Global impact of the COVID-19 pandemic on mental health services: a systematic review","volume":"154","author":"Duden","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2026.117346_bib0007","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jpsychires.2025.02.017","article-title":"Temporal trends of antipsychotic utilization patterns in 62,607 patients with schizophrenia-spectrum disorders in Hong Kong: An 11-year population-based study with joinpoint regression analysis","volume":"183","author":"Fang","year":"2025","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2026.117346_bib0008","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/bjb.2018.67","article-title":"Barriers to using clozapine in treatment-resistant schizophrenia: systematic review","volume":"43","author":"Farooq","year":"2019","journal-title":"BJPsych Bull."},{"key":"10.1016\/j.psychres.2026.117346_bib0009","article-title":"Global trends in clozapine utilisation between 2014 and 2024: a longitudinal epidemiological study with data from 75 countries","volume":"63","author":"Fitzgerald","year":"2026","journal-title":"Lancet Reg. Health\u2013Eur."},{"issue":"1","key":"10.1016\/j.psychres.2026.117346_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World Psychiatry"},{"issue":"12","key":"10.1016\/j.psychres.2026.117346_bib0011","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2215-0366(24)00314-6","article-title":"Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis","volume":"11","author":"H\u00f8jlund","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2026.117346_bib0012","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.euroneuro.2025.08.580","article-title":"Antipsychotic polypharmacy in patients with schizophrenia between 1999 and 2024 in Denmark: prevalence, time trends, and combinations","volume":"100","author":"H\u00f8jlund","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2026.117346_bib0014","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00019442-200309000-00007","article-title":"Patterns of public mental health service use by age in patients with schizophrenia","volume":"11","author":"Jin","year":"2003","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2026.117346_bib0015","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2026.117346_bib0016","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","article-title":"Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment","volume":"2","author":"Khandaker","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2026.117346_bib0017","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat. Med."},{"key":"10.1016\/j.psychres.2026.117346_bib0018","article-title":"A decade of Benzodiazepine and Z-drug use in Hong Kong: a longitudinal study","volume":"59","author":"Lee","year":"2025","journal-title":"Lancet Reg. Health\u2013West. Pac."},{"issue":"7","key":"10.1016\/j.psychres.2026.117346_bib0019","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.socscimed.2005.08.016","article-title":"Stigmatizing experience and structural discrimination associated with the treatment of schizophrenia in Hong Kong","volume":"62","author":"Lee","year":"2006","journal-title":"Soc. Sci. Med."},{"issue":"9657","key":"10.1016\/j.psychres.2026.117346_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.psychres.2026.117346_bib0021","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2026.117346_bib0022","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.psychres.2026.117346_bib0023","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/wps.21089","article-title":"Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis","volume":"22","author":"Leucht","year":"2023","journal-title":"World Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117346_bib0024","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotic","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.psychres.2026.117346_bib0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia\u2014an overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117346_bib0026","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2026.117346_bib0027","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/wps.20972","article-title":"Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants","volume":"21","author":"Ostuzzi","year":"2022","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2026.117346_bib0028","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"10.1016\/j.psychres.2026.117346_bib0029","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1177\/0004867418805559","article-title":"Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan","volume":"52","author":"Qiu","year":"2018","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2026.117346_bib0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1192\/bjp.2024.186","article-title":"Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000\u20132019: 20-year investigation of who receives treatment, with which agents and at what doses","volume":"226","author":"Richards-Belle","year":"2025","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117346_bib0031","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2215-0366(22)00032-3","article-title":"Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial","volume":"9","author":"Schmidt-Kraepelin","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2026.117346_bib0032","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.psychres.2018.06.070","article-title":"The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review","volume":"268","author":"Shah","year":"2018","journal-title":"Psychiatry Res."},{"issue":"11","key":"10.1016\/j.psychres.2026.117346_bib0033","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/2045125318782694","article-title":"Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec","volume":"8","author":"Stip","year":"2018","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2026.117346_bib0034","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/08039488.2020.1854853","article-title":"Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences","volume":"75","author":"Taipale","year":"2021","journal-title":"Nord. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2026.117346_bib0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2026.117346_bib0036","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2026.117346_bib0037","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","article-title":"Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia","volume":"76","author":"Tiihonen","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2026.117346_bib0038","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/wps.21316","article-title":"Effectiveness of clozapine augmentation with specific doses of other antipsychotics in schizophrenia: a meta-analysis from two nationwide cohorts","volume":"24","author":"Tiihonen","year":"2025","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2026.117346_bib0039","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/YIC.0000000000000086","article-title":"Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia","volume":"30","author":"\u00dc\u00e7ok","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2026.117346_bib0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.schres.2016.09.014","article-title":"Antipsychotic long-acting injections: a community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation","volume":"178","author":"Verdoux","year":"2016","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.psychres.2026.117346_bib0041","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2215-0366(25)00268-8","article-title":"Disease relapse, all-cause mortality, and adverse events associated with long-acting injectable antipsychotics versus oral antipsychotics in older people with schizophrenia in Hong Kong: a population-based within-subject analysis","volume":"12","author":"Wei","year":"2025","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2026.117346_bib0042","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.24163","article-title":"Association of long-acting injectable antipsychotics and oral antipsychotics with disease relapse, health care use, and adverse events among people with schizophrenia","volume":"5","author":"Wei","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.psychres.2026.117346_bib0043","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cns.13374","article-title":"Guidance on the clinical understanding and use of long-acting injectable antipsychotics in Schizophrenia: Hong Kong Consensus Statements","volume":"27","author":"Wong","year":"2021","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.psychres.2026.117346_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.02.056","article-title":"Clozapine prescription pattern in patients with schizophrenia in Asia: the REAP survey (2016)","volume":"287","author":"Xu","year":"2020","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.psychres.2026.117346_bib0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/brainsci14010006","article-title":"Global neuropsychopharmacological prescription trends in adults with schizophrenia, clinical correlates and implications for practice: a scoping review","volume":"14","author":"Ying","year":"2023","journal-title":"Brain Sci."}],"updated-by":[{"DOI":"10.1016\/j.psychres.2026.117385","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000}},{"DOI":"10.1016\/j.psychres.2026.117385","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000}}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126004063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126004063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:23:26Z","timestamp":1792052606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178126004063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S0165178126004063"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117346","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving patterns of antipsychotic use and polypharmacy for schizophrenia in Hong Kong: a 21-year longitudinal study","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117346"}}